iDenfy’s revamped AML Screening software now includes new risk categories, better PEP status labeling, and other built-in AML features The new iDenfy's AML Screening software redefines how companies ...
A total of 1482 adult AML patients were screened for DNMT3A mutations. One hundred and seventy-one adult AML patients (aged 18–87 years) were found to be DNMT3A mutated and had available diagnostic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback